Charles A. Gersbach
← Back to The Wallace H. Coulter Department of Biomedical Engineering
The Wallace H. Coulter Department of Biomedical Engineering
Charles A. Gersbach works in CRISPR and Genetic Engineering, Virus-based gene therapy research, Genomics and Chromatin Dynamics, RNA Interference and Gene Delivery, Pluripotent Stem Cells Research. Recorded institutional associations include Emory University, Duke University, The Wallace H. Coulter Department of Biomedical Engineering.
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
2013 · 3,811 citationsEpigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers
2015 · 1,885 citationsThe next generation of CRISPR–Cas technologies and applications
2019 · 1,455 citationsRNA-guided gene activation by CRISPR-Cas9–based transcription factors
2013 · 1,323 citationsIn vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
2015 · 1,141 citationsHighly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements
2015 · 1,006 citationsGenome-editing Technologies for Gene and Cell Therapy
2016 · 719 citationsA light-inducible CRISPR-Cas9 system for control of endogenous gene activation
2015 · 637 citationsMultiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy
2015 · 468 citationsEditing the epigenome: technologies for programmable transcription and epigenetic modulation
2016 · 449 citationsCRISPR–Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome
2017 · 444 citationsLong-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy
2019 · 430 citationsMultiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector
2014 · 383 citationsIncreasing the specificity of CRISPR systems with engineered RNA secondary structures
2019 · 351 citationsThe once and future gene therapy
2020 · 321 citationsHow vinculin regulates force transmission
2013 · 260 citationsSynergistic and tunable human gene activation by combinations of synthetic transcription factors
2013 · 242 citationsLoss-of-function genetic tools for animal models: cross-species and cross-platform differences
2016 · 220 citationsTargeted Epigenetic Remodeling of Endogenous Loci by CRISPR/Cas9-Based Transcriptional Activators Directly Converts Fibroblasts to Neuronal Cells
2016 · 219 citationsMyoblast proliferation and differentiation on fibronectin-coated self assembled monolayers presenting different surface chemistries
2004 · 203 citationsA CRISPR/Cas9-Based System for Reprogramming Cell Lineage Specification
2014 · 196 citationsLight-Inducible Spatiotemporal Control of Gene Activation by Customizable Zinc Finger Transcription Factors
2012 · 192 citationsReading Frame Correction by Targeted Genome Editing Restores Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients
2013 · 181 citationsRNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors
2018 · 178 citationsCas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models
2021 · 175 citations
